Table of Contents
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
1.2.1. Metabolism Drug Market, by region, 2020-2030 (USD Billion)
1.2.2. Metabolism Drug Market, by Drug Type, 2020-2030 (USD Billion)
1.2.3. Metabolism Drug Market, by Indication, 2020-2030 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Metabolism Drug Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Metabolism Drug Market Dynamics
3.1. Metabolism Drug Market Impact Analysis (2020-2030)
3.1.1. Market Drivers
3.1.1.1. Growing prevalence of Chronic Disease
3.1.1.2. Rising geriatric population
3.1.2. Market Challenges
3.1.2.1. High cost of metabolism drug
3.1.3. Market Opportunities
3.1.3.1. Growing pharmaceuticals industry
3.1.3.2. Increasing medical tourism
Chapter 4. Global Metabolism Drug Market: Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter's 5 Force Impact Analysis
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economic
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. COVID-19 Impact Analysis
4.7. Disruptive Trends
4.8. Industry Expert Perspective
4.9. Analyst Recommendation & Conclusion
Chapter 5. Global Metabolism Drug Market, by Drug Type
5.1. Market Snapshot
5.2. Global Metabolism Drug Market by Drug Type, Performance - Potential Analysis
5.3. Global Metabolism Drug Market Estimates & Forecasts by Drug Type 2020-2030 (USD Billion)
5.4. Metabolism Drug Market, Sub Segment Analysis
5.4.1. Antidiabetic Drugs
5.4.2. Lipid Lowering Drugs
5.4.3. Anti-Obesity Drugs
5.4.4. Thyroid Hormone Drugs
5.4.5. Others
Chapter 6. Global Metabolism Drug Market, by Indication
6.1. Market Snapshot
6.2. Global Metabolism Drug Market by Indication, Performance - Potential Analysis
6.3. Global Metabolism Drug Market Estimates & Forecasts by Indication 2020-2030 (USD Billion)
6.4. Metabolism Drug Market, Sub Segment Analysis
6.4.1. Diabetes
6.4.2. Hyperlipidaemia
6.4.3. Obesity
6.4.4. Hypothyroidism
Chapter 7. Global Metabolism Drug Market, Regional Analysis
7.1. Top Leading Countries
7.2. Top Emerging Countries
7.3. Metabolism Drug Market, Regional Market Snapshot
7.4. North America Metabolism Drug Market
7.4.1. U.S. Metabolism Drug Market
7.4.1.1. Drug Type breakdown estimates & forecasts, 2020-2030
7.4.1.2. Indication breakdown estimates & forecasts, 2020-2030
7.4.2. Canada Metabolism Drug Market
7.5. Europe Metabolism Drug Market Snapshot
7.5.1. U.K. Metabolism Drug Market
7.5.2. Germany Metabolism Drug Market
7.5.3. France Metabolism Drug Market
7.5.4. Spain Metabolism Drug Market
7.5.5. Italy Metabolism Drug Market
7.5.6. Rest of Europe Metabolism Drug Market
7.6. Asia-Pacific Metabolism Drug Market Snapshot
7.6.1. China Metabolism Drug Market
7.6.2. India Metabolism Drug Market
7.6.3. Japan Metabolism Drug Market
7.6.4. Australia Metabolism Drug Market
7.6.5. South Korea Metabolism Drug Market
7.6.6. Rest of Asia Pacific Metabolism Drug Market
7.7. Latin America Metabolism Drug Market Snapshot
7.7.1. Brazil Metabolism Drug Market
7.7.2. Mexico Metabolism Drug Market
7.8. Middle East & Africa Metabolism Drug Market
7.8.1. Saudi Arabia Metabolism Drug Market
7.8.2. South Africa Metabolism Drug Market
7.8.3. Rest of Middle East & Africa Metabolism Drug Market
Chapter 8. Competitive Intelligence
8.1. Key Company SWOT Analysis
8.1.1. Company 1
8.1.2. Company 2
8.1.3. Company 3
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. Merck Sharp & Dohme LLC
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Recent Developments
8.3.2. Novartis AG
8.3.3. Amicus Therapeutics Inc.
8.3.4. AstraZeneca PLC.
8.3.5. Boehringer Ingelheim International GmbH
8.3.6. Takeda Pharmaceutical Company Limited
8.3.7. Sanofi S.A.
8.3.8. GlaxoSmithKline PLC.
8.3.9. Horizon Therapeutics PLC
8.3.10. BioMarin Pharmaceutical Inc.
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
9.3. Research Assumption